The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC

摘要: Free to read The majority of patients with non-small-cell lung cancer (NSCLC) present advanced disease, targeted therapies providing some improvement in clinical outcomes. The epidermal growth factor receptor (EGFR) tyrosine kinase (TK) plays an important role the pathogenesis NSCLC. Tyrosine inhibitors (TKIs), which target EGFR TK domain, have proven be effective treatment strategy; however, patient responses vary considerably. Therefore, identification most likely respond is essential optimise benefit TKIs. Tumour-associated activating mutations can identify NSCLC who are a good response Nonetheless, relapse within year starting treatment. Studies tumours at demonstrated expression T790M mutation exon 20 domain approximately 50% cases. Although conferring resistance reversible TKIs, these may remain sensitive new-generation irreversible/panerb inhibitors. A number techniques been employed for genotypic assessment tumourassociated DNA mutations, each has advantages and disadvantages. This review presents overview current methodologies used such molecular markers. Recent developments technology make monitoring changes patients' tumour genotypes easier practice, enable regimens tailored during course their potentially leading improved